Literature DB >> 7690523

Hepatitis C virus in pregnancy: seroprevalence and risk factors for infection.

N S Silverman1, B K Jenkin, C Wu, P McGillen, G Knee.   

Abstract

OBJECTIVES: Our purpose was to define the prevalence of antibodies to hepatitis C virus among inner-city prenatal patients. We also sought to examine both the reliability of traditional hepatitis risk factors to predict evidence of infection among these women and the incidence of coinfection in this population with other blood-borne and sexually transmissible agents. STUDY
DESIGN: An anonymous serosurvey was performed to define and compare anti-hepatitis C virus prevalences among women registering for prenatal care at both an inner-city, university hospital-based clinic and an academic private practice based at the same institution.
RESULTS: Anti-hepatitis C virus antibodies were detected in 4.3% of 599 pregnant women screened. In comparison, 0.8% had positive antibody tests for human T-lymphotropic virus and 0.5% were positive for antibodies to human immunodeficiency virus. Evidence of chronic hepatitis B infection was seen in 0.8%. The relative risk of other coexisting infections was significantly higher among women with anti-hepatitis C virus antibodies than among those who were antibody negative. Substance abuse was the most commonly identified risk factor for anti-hepatitis C virus-positive status, although risk factor-targeted screening would have failed to detect half of the anti-hepatitis C virus-positive women in this study.
CONCLUSIONS: Hepatitis C virus infection among inner-city pregnant women, with its potential for maternal-fetal transmission, represents a public health issue of sufficient magnitude to warrant more extensive study. More information is needed, given this documented reservoir of maternal seropositivity, regarding the vertical transmissibility of the virus and the effects of coinfections on neonatal disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690523     DOI: 10.1016/0002-9378(93)90627-u

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

1.  HCV and pregnancy: prevalence, risk factors, and pregnancy outcome in north Indian population: a case-control study.

Authors:  Lajya Devi Goyal; Sharanjit Kaur; Neerja Jindal; Harpreet Kaur
Journal:  J Obstet Gynaecol India       Date:  2014-06-15

Review 2.  Hepatitis C virus in pregnancy.

Authors:  Mona R Prasad; Jonathan R Honegger
Journal:  Am J Perinatol       Date:  2013-02-06       Impact factor: 1.862

3.  Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort.

Authors:  Steven A Pergam; Chia C Wang; Carolyn M Gardella; Taylor G Sandison; Warren T Phipps; Stephen E Hawes
Journal:  Am J Obstet Gynecol       Date:  2008-05-19       Impact factor: 8.661

4.  Seroprevalence and risk factors for hepatitis C virus (HCV) infection in pregnant women attending public sector tertiary care hospital in Hyderabad Sindh.

Authors:  Seema Bibi; Saira Dars; Sanober Ashfaq; Roshan Ara Qazi; Sadaf Akhund
Journal:  Pak J Med Sci       Date:  2013-04       Impact factor: 1.088

5.  Frequency and the risk factors of hepatitis C virus in pregnant women; A hospital based descriptive study in Gadap Town Karachi.

Authors:  Kausar Jilani; Bushra Zulfiqar; Qadir Bux Memon; Muhammad Faisal Fahim
Journal:  Pak J Med Sci       Date:  2017 Sep-Oct       Impact factor: 1.088

6.  Previous history of surgery in females and roadside shaving in males are the commonest risk factors for hepatitis C infection: A cross-sectional retrospective study.

Authors:  Ajay Kumar Patwa; Amar Deep; Sushil Kumar; Sumit Rungta; Virendra Atam; Suchit Swaroop
Journal:  J Family Med Prim Care       Date:  2021-01-30

7.  Risk factors for hepatitis C infection among sexually transmitted disease-infected, inner city obstetric patients.

Authors:  Youyin Choy; Lisa Gittens-Williams; Joseph Apuzzio; Joan Skurnick; Carl Zollicoffer; Peter G McGovern
Journal:  Infect Dis Obstet Gynecol       Date:  2003
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.